AbbVie Net Profit Margin 2010-2023 | ABBV

Current and historical net profit margin for AbbVie (ABBV) from 2010 to 2023. Net profit margin can be defined as net Income as a portion of total sales revenue. AbbVie net profit margin for the three months ending December 31, 2023 was .
AbbVie Net Profit Margin Historical Data
Date TTM Revenue TTM Net Income Net Margin
2023-12-31 $54.32B $4.86B 8.95%
2023-09-30 $55.14B $6.51B 11.81%
2023-06-30 $56.02B $8.69B 15.50%
2023-03-31 $56.74B $7.59B 13.37%
2022-12-31 $58.05B $11.84B 20.39%
2022-09-30 $57.82B $13.41B 23.19%
2022-06-30 $57.35B $12.64B 22.04%
2022-03-31 $56.73B $12.48B 22.00%
2021-12-31 $56.20B $11.54B 20.54%
2021-09-30 $55.17B $7.53B 13.66%
2021-06-30 $53.73B $6.66B 12.40%
2021-03-31 $50.20B $5.16B 10.28%
2020-12-31 $45.80B $4.62B 10.08%
2020-09-30 $40.65B $7.38B 18.16%
2020-06-30 $36.23B $6.96B 19.20%
2020-03-31 $34.06B $8.44B 24.77%
2019-12-31 $33.27B $7.88B 23.69%
2019-09-30 $32.87B $3.26B 9.90%
2019-06-30 $32.62B $4.12B 12.62%
2019-03-31 $32.65B $5.36B 16.42%
2018-12-31 $32.75B $5.69B 17.36%
2018-09-30 $32.19B $7.57B 23.50%
2018-06-30 $30.95B $6.45B 20.84%
2018-03-31 $29.61B $6.38B 21.55%
2017-12-31 $28.22B $5.31B 18.82%
2017-09-30 $27.27B $6.65B 24.38%
2017-06-30 $26.71B $6.62B 24.77%
2017-03-31 $26.22B $6.31B 24.07%
2016-12-31 $25.64B $5.95B 23.22%
2016-09-30 $25.24B $6.08B 24.08%
2016-06-30 $24.75B $5.72B 23.11%
2016-03-31 $23.78B $5.48B 23.03%
2015-12-31 $22.86B $5.14B 22.50%
2015-09-30 $21.91B $2.82B 12.86%
2015-06-30 $20.99B $2.08B 9.93%
2015-03-31 $20.44B $1.82B 8.89%
2014-12-31 $19.96B $1.77B 8.89%
2014-09-30 $19.62B $3.71B 18.92%
2014-06-30 $19.26B $4.17B 21.65%
2014-03-31 $19.02B $4.14B 21.76%
2013-12-31 $18.79B $4.13B 21.97%
2013-09-30 $18.89B $4.54B 24.04%
2013-06-30 $18.74B $5.16B 27.55%
2013-03-31 $18.54B $5.36B 28.92%
2012-12-31 $18.38B $5.28B 28.70%
2012-09-30 $18.04B $4.89B 27.12%
2012-06-30 $17.94B $3.32B 18.51%
2012-03-31 $17.72B $3.59B 20.28%
2011-12-31 $17.44B $3.43B 19.68%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $287.341B $54.318B
AbbVie has become one of the top-most pharma companies after it acquired Allergan. The deal has transformed AbbVie's portfolio by lowering its dependence on Humira, its flagship product. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest immunology drugs Skyrizi and Rinvoq position it well for long-term growth. AbbVie came into existence after Abbott Laboratories divested its pharmaceutical division. AbbVie enjoys leadership positions in key therapeutic areas including immunology, hematologic oncology, neuroscience, aesthetics, eye care and womens' health. Humira is approved for several autoimmune diseases like rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis, Crohn's disease and others. Imbruvica became part of the company's portfolio following the Pharmacyclics acquisition. Other key drugs include Venclexta, Botox Cosmetic, Botox Therapeutics, Vraylar, Skyrizi and Rinvoq.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $714.182B 118.93
Novo Nordisk (NVO) Denmark $558.743B 46.03
Johnson & Johnson (JNJ) United States $355.491B 14.14
Merck (MRK) United States $318.503B 83.83
AstraZeneca (AZN) United Kingdom $213.711B 18.94
Novartis AG (NVS) Switzerland $198.225B 13.73
Pfizer (PFE) United States $146.433B 14.13
Sanofi (SNY) $116.185B 10.46
Innoviva (INVA) United States $0.925B 6.53